Eli Lilly (NYSE:LLY) Q2 Revenue Rises 28% to $8.31 Bln, Well Above the FactSet Consensus of $7.58 Bln。
Eli Lilly (NYSE:LLY) Q2 Revenue Rises 28% to $8.31 Bln，Above the FactSet Consensus Read Post »
Eli Lilly (NYSE:LLY) Raises FY23 Revenue Guidance To $33.4B-$33.9B From Prior Guidance Of $31.2B-$31.7B Vs. Consensus Of $31.44B; Sees Adjusted EPS Of $9.70-$9.90 From Prior Guidance Of $8.65-$8.85 Vs. Consensus Of $8.71
Eli Lilly (NYSE:LLY) Raises FY23 Revenue Guidance To $33.4B-$33.9B Read Post »
Barclays Adjusts Biogen (NASDAQ:BIIB) Price Target to $294 From $311, Maintains Equal Weight Rating.
Barclays Adjusts Biogen (NASDAQ:BIIB) Price Target to $294 From $311 Read Post »
Raymond James analyst John Ransom maintains Cigna Group (NYSE:CI) with a Strong Buy and raises the price target from $310 to $330.
Raymond James raises Cigna Group (NYSE:CI) price target from $310 to $330 Read Post »
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and lowers the price target from $350 to $343.
Wells Fargo lowers Biogen (NASDAQ:BIIB) price target from $350 to $343 Read Post »
Barclays analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $888 to $900.
Barclays raises Regeneron Pharmaceuticals (NASDAQ:REGN) price target from $888 to $900 Read Post »
Deutsche Bank Adjusts Humana (NYSE:HUM) Price Target to $628 From $568, Maintains Buy Rating.
Deutsche Bank Adjusts Humana (NYSE:HUM) Price Target to $628 From $568 Read Post »
Bank of America Securities analyst Geoff Meacham maintains Moderna (NASDAQ:MRNA) with a Neutral and lowers the price target from $175 to $150.
Bank of America lowers Moderna (NASDAQ:MRNA) price target from $175 to $150 Read Post »
Goldman Sachs Adjusts Price Target on Gilead Sciences (NASDAQ:GILD) to $85 From $84, Maintains Neutral Rating.
Goldman Sachs Adjusts Price Target on Gilead Sciences (NASDAQ:GILD) to $85 From $84 Read Post »
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $83 to $84.
RBC Capital raises Gilead Sciences (NASDAQ:GILD) price target from $83 to $84 Read Post »
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $897 to $912.
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $379 to $374.
RBC Capital lowers Biogen (NASDAQ:BIIB) price target from $379 to $374 Read Post »